Prognostic Factors in Patients Receiving Neoadjuvant 5-Fluorouracil plus Cisplatin for Advanced Esophageal Cancer (JCOG9907)
- 16 April 2015
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 89 (3), 143-151
- https://doi.org/10.1159/000381065
Abstract
Objective: Neoadjuvant chemotherapy with 5-fluorouracil plus cisplatin and subsequent esophagectomy with two- to three-field lymphadenectomy is a standard treatment for patients with clinical stage II/III squamous cell carcinoma (SCC) of the esophagus. This study investigates the prognostic factors for patients who received neoadjuvant chemotherapy. Methods: Of 164 patients assigned to receive neoadjuvant chemotherapy in the JCOG9907 trial, multivariate analyses were performed for 159 and 149 patients to evaluate the preoperative and the combined preoperative and postoperative prognostic factors, respectively. Results: The multivariate analyses using preoperative factors showed that clinical stage T3 [vs. cT1-2; hazard ratio (HR) 3.60, p = 0.0007] and serum albumin (Alb) <4.0 g/dl (vs. ≥4.0 g/dl; HR 2.29, p = 0.0005) were associated with a poor prognosis. Four independent prognostic factors were identified by multivariate analysis of both preoperative and postoperative factors: pathological curability B (pB; R0 with stage IV or pD < pN) or pC [microscopic or macroscopic residual tumor (R1/R2)] [vs. pA (R0); HR 1.93, p = 0.015], pathological stage N1 (vs. pN0; HR 3.86, p = 0.0012), cT3 (vs. cT1-2; HR 2.80, p = 0.0073), and serum Alb <4.0 g/dl (vs. ≥4.0 g/dl; HR 2.03, p = 0.0069). Conclusions: Preoperative cT stage, Alb, and postoperative pathological findings are independent prognostic factors for patients undergoing neoadjuvant chemotherapy for advanced thoracic esophageal SCC. This analysis may aid in stratification according to individual patient risk.Keywords
This publication has 18 references indexed in Scilit:
- The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancerMedical Oncology, 2013
- Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer17British Journal of Surgery, 2012
- A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)Annals of Surgical Oncology, 2011
- A Multicenter Study of Survival After Neoadjuvant Radiotherapy/Chemotherapy and Esophagectomy for ypT0N0M0R0 Esophageal CancerAnnals of Surgery, 2010
- Role of Systemic Inflammatory Response in Predicting Survival in Patients with Primary Operable CancerFuture Oncology, 2009
- Long-term Outcomes Following Neoadjuvant Chemoradiotherapy for Esophageal CancerAnnals of Surgery, 2007
- Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Carcinoma Is Associated With Significantly Improved SurvivalJournal of Clinical Oncology, 2005
- Guidelines for clinical and pathologic studies on carcinoma of the esophagus, ninth edition: Preface, general principles, part IEsophagus, 2004
- Mortality and Morbidity Rates, Postoperative Course, Quality of Life, and Prognosis After Extended Radical Lymphadenectomy for Esophageal GancerAnnals of Surgery, 1995
- Evaluation of neck lymph node dissection for thoracic esophageal carcinomaThe Annals of Thoracic Surgery, 1991